A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer

Glasspool, R.M. et al. (2014) A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer. British Journal of Cancer, 110(8), pp. 1923-1929. (doi: 10.1038/bjc.2014.116)

Abstract

With this schedule, the addition of decitabine appears to reduce rather than increase the efficacy of carboplatin in partially platinum-sensitive ovarian cancer and is difficult to deliver. Patient-selection strategies, different schedules and other demethylating agents should be considered in future combination studies.

• Item Type: Articles
• Status: Published
• Refereed: Yes
• Glasgow Author(s) Enlighten ID: Wilson, Professor Richard and Kaye, Professor Stanley and Ullah, Dr Robina and Paul, Mr James and Mcneish, Professor Iain and Appleton, Ms Kim
• Authors: Glasspool, R.M., Brown, R., Gore, M.E., Rustin, G.J.S., McNeish, I.A., Wilson, R.H., Pledge, S., Paul, J., Mackean, M., Hall, G.D., Gabra, H., Halford, S.E.R., Walker, J., Appleton, K., Ullah, R., and Kaye, S.
• Subjects: R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
• College/School: College of Medical Veterinary and Life Sciences > School of Cancer Sciences; College of Medical Veterinary and Life Sciences > School of Health & Wellbeing > Mental Health and Wellbeing
• Journal Name: British Journal of Cancer
• Publisher: Nature Publishing Group
• ISSN: 0007-0920
• ISSN (Online): 1532-1827
• Copyright Holders: Copyright © 2014 4 Cancer Research UK
• First Published: First published in British Journal of Cancer 110(8):1923-1929
• Publisher Policy: Reproduced under a Creative Commons License